New blood tests could simplify Wilson's disease monitoring

NCT ID NCT07462026

Completed Knowledge-focused Sponsor: Hacettepe University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at two new blood tests, called exchangeable copper (EC) and relative exchangeable copper (REC), to see if they could better monitor Wilson's disease than standard tests. Researchers compared these blood tests with usual copper measurements in 81 adult patients with Wilson's disease and a control group. The goal was to see if EC and REC could provide a simpler and more accurate way to track the disease during follow-up.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, these blood tests could offer a simpler, more accurate way to monitor Wilson's disease, potentially replacing 24-hour urine collections.
What could go wrong: This is a small, completed observational study, not a treatment trial. The tests may not prove more useful than existing methods in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WILSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Wilson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

WILSON'S DISEASE

Contacts and locations

Locations

Hacettepe Üniversitesi İç Hastalıkları Anabilim Dalı

Ankara, Sıhhıye, 06100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.